Niagen Bioscience Inc

NAGE· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$3.53+3.82%

2026-08-03

Financials

Valuation Metrics

Niagen Bioscience Inc's Market Cap is $281M. At end of 2025 it was $502M. Ranked #2973 of 3,112 in US market (top 96%), #1339 of 1,445 on NASDAQ (top 93%), #246 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$281M	US#2,973/3,112 Sec#246/269
Revenue	$130M	US#2,751/3,112 Sec#121/269
Net Income	$19M	US#2,079/3,112 Sec#70/269
Total Assets	$114M	US#3,029/3,112 Sec#262/269
Net Assets	$82M	US#2,896/3,112 Sec#232/269
Value
P/E	15.09x	US#685/3,112 Sec#26/269
P/B	3.41x	US#1,818/3,112 Sec#105/269
PEG	0.61x	US#644/3,112 Sec#26/269
P/S	2.16x	US#1,342/3,112 Sec#34/269
EV/EBITDA	10.15x	US#782/3,112 Sec#30/269
FCF Yield	1.46%	US#2,058/3,112 Sec#72/269
Profitability
ROE	22.64%	US#478/3,112 Sec#33/269
ROA	16.30%	US#171/3,112 Sec#26/269
Op. Margin	8.51%	US#1,746/3,112 Sec#70/269
Revenue Growth	3.26%	US#1,918/3,112 Sec#117/269
Earnings Growth	24.79%	US#843/3,112 Sec#33/269
Financial Health
Debt Ratio	38.87%	US#441/3,112 Sec#124/269
Total Debt	$3M	US#2,896/3,112 Sec#232/269
FCF	$4M	US#2,238/3,112 Sec#84/269
Cash	$67M	US#2,446/3,112 Sec#206/269
Current Ratio	4.61x	US#522/3,112 Sec#158/269
Net Debt/EBITDA	-2.99x	US#124/3,112 Sec#7/269
Performance
1Y Return	-60.95%	US#3,057/3,112 Sec#259/269
1M Return	2.92%	US#1,223/3,112 Sec#50/269
From 52W High	-68.73%	US#3,005/3,112 Sec#251/269
1Y MDD	-77.03%	US#3,020/3,112 Sec#255/269
Trading
Volume	1,250,383 shares	US#1,289/3,112 Sec#127/269
Trading Value	$4M	US#2,712/3,112 Sec#224/269
Per Share
EPS	$0.22	US#1,962/3,112 Sec#69/269
BPS	$0.97	US#2,625/3,112 Sec#202/269